Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study

References

• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):1–19. doi: 10.1002/hep.29367.
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039.
   PubMed Web of Science ®Google Scholar
• Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700. doi: 10.1210/clinem/dgac321.
   PubMed Web of Science ®Google Scholar
• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. doi: 10.1016/S0140-6736(21)01374-X.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397 e10. doi: 10.1053/j.gastro.2015.04.043.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273. doi: 10.1016/j.jhep.2017.07.027.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–457 e17. doi: 10.1053/j.gastro.2018.04.034.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898–1906. doi: 10.1053/j.gastro.2005.03.084.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver, Asociacion Latinoamericana Para el estudio del H. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. doi: 10.1002/hep.21496.
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112. doi: 10.1016/j.cgh.2009.05.033.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–1447. doi: 10.1136/gut.2007.146019.
   PubMed Web of Science ®Google Scholar
• Kolhe KM, Amarapurkar A, Parikh P, et al. Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. BMJ Open Gastroenterol. 2019;6(1):e000288. doi: 10.1136/bmjgast-2019-000288.
   PubMed Web of Science ®Google Scholar
• Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int. 2017;37(9):1389–1396. doi: 10.1111/liv.13397.
   PubMed Web of Science ®Google Scholar
• Wu J, Lu AD, Zhang LP, et al. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):52–57.
   PubMedGoogle Scholar
• Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the rotterdam study. Hepatology. 2016;63(1):138–147. doi: 10.1002/hep.27981.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi: 10.1053/jhep.2003.50346.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431.
   PubMed Web of Science ®Google Scholar
• Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605–1616. doi: 10.1002/hep.31173.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345–352. doi: 10.1080/17474124.2021.1860019.
   PubMed Web of Science ®Google Scholar
• Demirtas CO, Yilmaz Y. Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice? Hepatol Forum. 2020;1(3):79–81. doi: 10.14744/hf.2020.2020.0024.
   PubMedGoogle Scholar
• Alharthi J, Gastaldelli A, Cua IH, et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260. doi: 10.1097/MOG.0000000000000823.
   PubMed Web of Science ®Google Scholar
• Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619–629 e7. doi: 10.1016/j.cgh.2021.11.038.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Le MH, Cheung RC, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181 e6. doi: 10.1016/j.cgh.2021.05.029.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1100–1109. doi: 10.1111/apt.16595.
   PubMed Web of Science ®Google Scholar
• Xing Y, Chen J, Liu J, et al. Associations between GGT/HDL and MAFLD: a cross-sectional study. Diabetes Metab Syndr Obes. 2022;15:383–394. doi: 10.2147/DMSO.S342505.
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171 e5. doi: 10.1016/j.cgh.2020.10.046.
   PubMed Web of Science ®Google Scholar
• Sohn W, Kwon HJ, Chang Y, et al. Liver fibrosis in asians with metabolic dysfunction-associated fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(5):e1135–e1148. doi: 10.1016/j.cgh.2021.06.042.
   PubMed Web of Science ®Google Scholar
• Kim M, Yoon EL, Cho S, et al. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in korea. Liver Int. 2022;42(7):1536–1544. doi: 10.1111/liv.15259.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Wang H, Gao P, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in beijing, China. Int J Environ Res Public Health. 2022;19(4):2096. doi: 10.3390/ijerph19042096.
   Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089. doi: 10.1111/liv.14548.
   PubMed Web of Science ®Google Scholar
• Hwang TI, Han AL. Quality of life in adults with metabolic dysfunction-associated fatty liver disease. Int J Environ Res Public Health. 2021;18(24):13145. doi: 10.3390/ijerph182413145.
   PubMed Web of Science ®Google Scholar
• Attia D, Aty NA, Shawket A, et al. MAFLD not NAFLD is associated with impairment of health-related quality of life. J Clin Transl Hepatol. 2022;10(1):4–5. doi: 10.14218/JCTH.2021.00485.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625 e12. doi: 10.1053/j.gastro.2020.01.043.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. doi: 10.1002/hep.29085.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559–1569. doi: 10.1056/NEJMoa2029349.
   PubMed Web of Science ®Google Scholar
• Yang RX, Zou ZS, Zhong BH, et al. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: a multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int. 2021;20(5):426–432. doi: 10.1016/j.hbpd.2021.06.002.
   PubMed Web of Science ®Google Scholar
• Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: an update. J Diabetes Investig. 2022;13(6):930–940. doi: 10.1111/jdi.13756.
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Perseghin G. Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2022;190:109981. doi: 10.1016/j.diabres.2022.109981.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475–485. doi: 10.3748/wjg.v20.i2.475.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-Controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156–163 e2. doi: 10.1016/j.cgh.2018.04.043.
   PubMed Web of Science ®Google Scholar
• Aykut UE, Akyuz U, Yesil A, et al. A comparison of FibroMeter NAFLD score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand J Gastroenterol. 2014;49(11):1343–1348. doi: 10.3109/00365521.2014.958099.
   PubMed Web of Science ®Google Scholar
• Wong VW, Irles M, Wong GL, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68(11):2057–2064. doi: 10.1136/gutjnl-2018-317334.
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–1501. doi: 10.1002/hep.29302.
   PubMed Web of Science ®Google Scholar
• Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006–1019. doi: 10.1136/gutjnl-2021-324243.
   PubMed Web of Science ®Google Scholar
• Ismaiel A, Leucuta DC, Popa SL, et al. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis. Panminerva Med. 2021;63(4):508–518. doi: 10.23736/S0031-0808.20.04171-3.
   PubMed Web of Science ®Google Scholar
• Kaya E, Bakir A, Kani HT, et al. Simple noninvasive scores are clinically useful to exclude, not predict, advanced fibrosis: a study in Turkish patients with biopsy-proven nonalcoholic fatty liver disease. Gut Liver. 2020;14(4):486–491. doi: 10.5009/gnl19173.
   PubMed Web of Science ®Google Scholar
• Eren F, Kaya E, Yilmaz Y. Accuracy of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol. 2022;34(1):98–103. doi: 10.1097/MEG.0000000000001946.
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751. doi: 10.1038/ajg.2016.453.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi: 10.1007/s12072-020-10094-2.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O . EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65–90.
   PubMed Web of Science ®Google Scholar
• Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. doi: 10.1002/hep.24452.
   PubMed Web of Science ®Google Scholar
• Salmi A, di Filippo L, Ferrari C, et al. Ultrasound and FibroScan((R)) controlled attenuation parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine. 2022;78(2):262–269. doi: 10.1007/s12020-022-03157-x.
   PubMed Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–750. doi: 10.1053/gast.2002.35354.
   PubMed Web of Science ®Google Scholar
• Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51(3):433–445. doi: 10.1016/j.jhep.2009.05.023.
   PubMed Web of Science ®Google Scholar